Vedolizumab Drug Antibodies (ENTYVIO drug antibodies)

Immunology

Description

Vedolizumab is a therapeutic antibody against alpha-4 beta-7 integrin which is predominantly expressed by T cells with gastrointestinal-homing mechanisms. Vedolizumab binds to this integrin on activated lymphocytes and stops the migration into the intestinal mucosa. Thus, vedolizumab works to suppresses the inflammatory response [1,2]. It is used in the treatment of conditions such as active ulcerative colitis and Crohn’s disease.

Ongoing use of vedolizumab may initiate an immune response in a small subgroup of patients, leading to the production of anti-vedolizumab antibodies [3]. These antibodies can neutralise the effect of the drug. Patients with positive anti-vedolizumab antibodies are more likely to have loss of response to therapy over time.

The measurement of vedolizumab drug levels and vedolizumab antibody levels can aid in clinical decision making by identifying if a trough therapeutic drug level has been reached and determining if anti-drug antibodies are present if the trough level is low. The result can be used to guide the ongoing treatment options.

Indications

Investigation of low trough Vedolizumab levels or in patients experiencing adverse reactions following Vedolizumab infusion.

Sample Type

2mL Serum (Gel 5mL Yellow tube) or 2mL Plasma (EDTA). Requests from outside Sheffield: Transport at ambient temperature via Royal Mail or Courier.

Reference Range

Negative = <10 AU/mL

Turnaround Time

10 days

Testing Frequency

As required

References

Pouillon L, Vermeire S and Bossuyt. Vedolizumab trough level monitroing in inflammatory bowel disease: a state of the art overview. BMC Med. 2019. 17:89 [Ref 1]. Hui S, Sinopoulou V, Gordon M, et al. Vedolizumab for induction and maintenance of remission in Crohn’s disease. Cochrane database of systematic reviews. 2023. Issue 7. Art No, CD013611. [Ref 2]. Wyant T, Yang L, Lirio RA, et al. Vedolizumab immunogenicity with long-term or interuppted treatemtn of patients with inflammatory bowel disease. The journal of Clin Pharmacol. 2021. 61(9): 1174-1181. [Ref 3].

See Also

Vedolizumab drug level

Please note: the above information is subject to change and we endeavour to keep this website up to date wherever necessary.

Your contact for this test

You are enquiring about

Vedolizumab Drug Antibodies (ENTYVIO drug antibodies)